UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

October 27, 2016

 

 

PROQR THERAPEUTICS N.V.

 

 

Zernikedreef 9

2333 CK Leiden

The Netherlands

Tel: +31 88 166 7000

(Address, Including ZIP Code, and Telephone Number,

Including Area Code, of Registrant’s Principal Executive Offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


On October 27, 2016, ProQR Therapeutics N.V. issued a press releases titled, “ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous D F508 Cystic Fibrosis Patients.” A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    PROQR THERAPEUTICS N.V.
Date: October 27, 2016     By:  

/s/ Smital Shah

      Smital Shah
      Chief Financial Officer


INDEX TO EXHIBITS

 

Number

  

Description

99.1    Press Release of ProQR Therapeutics N.V. dated October 27, 2016, titled “ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous D F508 Cystic Fibrosis Patients.”
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more ProQR Therapeutics NV Charts.
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more ProQR Therapeutics NV Charts.